Clinical risk factors for invasive aspergillosis.
Despite improvements in the antifungal armamentarium and diagnostic modalities, invasive aspergillosis (IA) remains an important cause of morbidity and mortality in immunocompromised patients. There is an emergence of non-traditional groups at risk for IA, including intensive care unit (ICU) patients, post-operative patients, those with chronic pulmonary diseases, patients with AIDS and patients on immunomodulating drugs (TNF-α inhibitors). Identification of clinical risk factors for IA may help in determining which patients require risk modification and other prevention measures.
Baddley
John W
JW
University of Alabama at Birmingham, and Birmingham Veterans Affairs Medical Center, 1900 University Boulevard, Birmingham, AL 35294, USA. jbaddley@uab.edu
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D001228:Aspergillosis / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control*; D001230:Aspergillus / Q000472:pathogenicity; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007362:Intensive Care Units; D016377:Organ Transplantation / Q000009:adverse effects; D011183:Postoperative Complications / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha